SIETES :: 93212 citas

Resultados de la búsqueda por ALZHEIMER REFINAR BÚSQUEDA

1.

Weigand AJ, Bondi.MW, Thomas KR, Campbell NL, et al.. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology 2020;95:e2295-304. [Ref.ID 103815]

2.

Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Rajagopalan B, On behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias. A scientific statement from the American Heart Association. Circulation 2020;142:16 de septiembre. [Ref.ID 103712]

3.

Niznik JD, Zhao X, He M, Aspinall SL, Hanlon JT, Hanson LC, Nace D, Thorpe JM, Thorpe CT. Risk for health events after deprescribing acetylcholinesterase inhibitors in nursing home residents with severe dementia. J Am Geriatr Soc 2020;68:699-707. [Ref.ID 103640]

4.

Khan MA, Yuan Y, Iqbal U, Kamal S, Khan M, Khan Z, Lee W, Howden CW. No association linking short-term proton pump inhibitor use to dementia: Systematic review and meta-analysis of observational studies. The American Journal of Gastroenterology 2020;115:mayo. [Ref.ID 103525]

5.

Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ 2020;367:17 de enero. [Ref.ID 103511]

6.

Blanco-Silvente L, Castells X, Garre-Olmo J, Vilalta-Franch J, Saez M, Barceló MA, Capellà D. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103212]

7.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019;179:agosto. [Ref.ID 103160]

8.

Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]

9.

Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]

10.

Liu B, Luo Z, Pinto JM, Shiroma EJ, Tranah GJ, Wirdefeldt K, Fang F, Harris TB, Chen H. Relationship between poor olfaction and mortality among community-dwelling older adults: a cohort study. Ann Intern Med 2019:30 de abril. [Ref.ID 103093]

11.

Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019;364:6 de marzo. [Ref.ID 103059]

12.

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

13.

Ranson JM, Kuzma E, Hamilton W, Muniz-Terrera G, Langa KM, Llewellyn DJ. Predictors of dementia misclassification when using brief cognitive assessments. Neurology: Clinical Practice 2018:28 de noviembre. [Ref.ID 102864]

14.

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

15.

Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]

16.

Garde D. Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment. STAT Daily Recap 2018:1. [Ref.ID 102726]

17.

Garde D. Biogen reports positive results with Alzheimer’s drug, reviving hopes for once-failed treatment. STAT Daily Recap 2018:1. [Ref.ID 102725]

18.

Anónimo. Synthetic cannabinoid may improve agitation and aggression in Alzheimer’s disease patients, research suggests. DIA Daily 2018:26 de julio. [Ref.ID 102724]

19.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]

20.

Gray SL, Walker RL, Dublin S, Yu O, Aielo Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc 2018;66:febrero. [Ref.ID 102537]